VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
HOLXHologic, Inc.
$76.01$17.0B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksHOLXFinancials

Hologic, Inc. (HOLX) Financials

30Y historyFree accessUpdated daily

Revenue growth remains constrained at 2.5% in 2026Q1, while gross margins have fluctuated significantly from a low of 37.5% in 2025Q2 to 56.0% in the most recent quarter.

HOLX Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMSep'25Sep'24Sep'23Sep'22Sep'21Sep'20Sep'19Sep'18Sep'17Sep'16Sep'15Sep'14Sep'13Sep'12Sep'11Sep'10Sep'09Sep'08Sep'07Sep'06Sep'05Sep'04Sep'03Sep'02Sep'01Sep'00Sep'99Sep'98Sep'97Sep'96
Sales/Revenue4.13B4.1B4.03B4.03B4.86B5.63B3.78B3.37B3.22B3.06B2.83B2.71B2.53B2.49B2B1.79B1.68B1.64B1.67B738.37M462.68M287.68M228.71M204.03M190.19M178.49M93.75M84.1M115.6M106.7M88.2M
Revenue Growth %2.16%1.74%-0%-17.12%-13.66%49.14%12.15%4.64%5.2%7.98%4.72%6.89%1.54%24.45%11.92%6.54%2.59%-2.23%126.78%59.59%60.83%25.79%12.09%7.28%6.56%90.4%11.47%-27.25%8.34%20.98%103.23%
Cost of Goods Sold1.95B1.6B1.8B1.96B1.87B1.84B1.55B2.06B1.52B1.44B1.27B1.27B1.29B1.33B1.01B866.17M942.91M779.65M781.98M392.8M269.15M174.66M143.34M130.46M118.38M116.18M59.18M46.8M54M46.2M40.4M
COGS % of Revenue-39.01%44.72%48.6%38.36%32.61%41.02%61.15%47.27%47.01%44.81%47.04%50.78%53.4%50.34%48.41%56.14%47.62%46.7%53.2%58.17%60.71%62.67%63.94%62.24%65.09%63.13%55.65%46.71%43.3%45.8%
Gross Profit2.18B2.5B2.23B2.07B3B3.8B2.23B1.31B1.7B1.62B1.56B1.43B1.25B1.16B994.44M923.18M736.64M857.49M892.52M345.57M193.53M113.03M85.37M73.58M71.82M62.31M34.56M37.3M61.6M60.5M47.8M
Gross Margin %52.82%60.99%55.28%51.4%61.64%67.39%58.98%38.85%52.73%52.99%55.19%52.96%49.22%46.6%49.66%51.59%43.86%52.38%53.3%46.8%41.83%39.29%37.33%36.06%37.76%34.91%36.87%44.35%53.29%56.7%54.2%
Gross Profit Growth %-12.27%7.55%-30.89%-21.03%70.41%70.29%-22.9%4.67%3.69%9.12%15.03%7.24%16.79%7.72%25.32%-14.09%-3.93%158.28%78.56%71.23%32.4%16.02%2.46%15.25%80.3%-7.34%-39.45%1.82%26.57%118.26%
Operating Expenses1.46B1.79B1.35B1.4B1.36B1.32B1.12B1.18B1.19B1.14B1B949.1M908.5M880.06M745.81M536.05M566.28M533.34M518.48M197.81M123.29M80.39M72.78M70.56M67.59M79.6M61.92M46.9M50.8M38.1M35.7M
OpEx % of Revenue-43.58%33.38%34.81%27.91%23.36%29.72%35.08%36.94%37.18%35.45%35.09%35.9%35.31%37.24%29.96%33.72%32.58%30.96%26.79%26.65%27.95%31.82%34.58%35.54%44.6%66.05%55.77%43.94%35.71%40.48%
Selling, General & Admin1.07B1.07B994.8M987.6M1.04B994.4M840.3M897.2M910.7M841.9M682.4M624M591.5M569.82M542.36M445.52M407.12M387.8M408.93M147.75M98.46M61.78M56.12M52.17M47.23M56.27M40.32M30.7M39.1M28.3M34.8M
SG&A % of Revenue-26.09%24.68%24.5%21.35%17.66%22.25%26.64%28.3%27.52%24.09%23.07%23.37%22.86%27.08%24.9%24.24%23.69%24.42%20.01%21.28%21.47%24.54%25.57%24.83%31.53%43.01%36.5%33.82%26.52%39.46%
Research & Development248.5M248.2M272.8M294.3M283.4M276.3M222.5M232.2M218.7M232.8M232.1M214.9M203.2M197.65M130.96M116.7M104.31M94.33M81.42M44.48M28.29M18.62M16.66M18.38M20.36M23.33M17.18M12.7M9.8M8.5M7.3M
R&D % of Revenue-6.05%6.77%7.3%5.83%4.91%5.89%6.9%6.8%7.61%8.19%7.94%8.03%7.93%6.54%6.52%6.21%5.76%4.86%6.02%6.12%6.47%7.28%9.01%10.71%13.07%18.32%15.1%8.48%7.97%8.28%
Other Operating Expenses4M468.7M77.6M121.2M35.8M44.8M59.7M52M7.6M12.9M26.6M-11M-3.6M3.6M7.26M-4.18M901K00000000000000
Operating Income721.6M714.3M882.6M668.4M1.64B2.48B1.1B134.4M-237.9M1.37B548.6M455.1M279.7M-906.28M113.72M374.44M69.94M-2.02B-197.54M147.75M50.34M32.63M12.59M3.02M2.16M-18.81M-27.36M-9.6M10.8M22.4M12.1M
Operating Margin %17.49%17.42%21.9%16.58%33.73%44.04%29.26%3.99%-7.39%44.8%19.37%16.82%11.05%-36.36%5.68%20.93%4.16%-123.18%-11.8%20.01%10.88%11.34%5.5%1.48%1.13%-10.54%-29.18%-11.42%9.34%20.99%13.72%
Operating Income Growth %--19.07%32.05%-59.25%-33.87%124.46%722.17%156.49%-117.36%149.76%20.54%62.71%130.86%-896.96%-69.63%435.4%103.47%-920.88%-233.7%193.51%54.27%159.26%316.07%40.24%111.47%31.26%-184.99%-188.89%-51.79%85.12%157.45%
EBITDA973.7M1.01B1.19B991.8M2.07B2.89B1.48B597.4M242.4M1.82B1.01B946.5M393.5M-793.68M185.75M432.78M124.8M-1.97B-24.59M178.91M66.47M40.2M20.18M10.43M9.63M-10.07M-22.94M-6.1M12.7M23.7M13M
EBITDA Margin %23.6%24.73%29.57%24.61%42.57%51.26%39.22%17.74%7.53%59.48%35.8%34.99%15.55%-31.85%9.28%24.19%7.43%-120.06%-1.47%24.23%14.37%13.98%8.82%5.11%5.06%-5.64%-24.47%-7.25%10.99%22.21%14.74%
EBITDA Growth %-21.58%-14.9%20.15%-52.09%-28.29%94.95%147.91%146.45%-86.68%79.43%7.13%140.53%149.58%-527.28%-57.08%246.79%106.35%-7892.29%-113.75%169.16%65.33%99.28%93.43%8.27%195.65%56.1%-276.05%-148.03%-46.41%82.31%145.28%
D&A (Non-Cash Add-back)252.1M299.8M309M323.4M430.1M406.9M376M463M480.3M449.2M465.4M491.4M113.8M112.6M72.04M58.33M54.86M51.21M172.95M31.16M16.13M7.57M7.59M7.41M7.48M8.73M4.42M3.5M1.9M1.3M900K
EBIT761.8M723.9M987.2M787.2M1.68B2.45B1.12B-116.9M-269.9M1.38B570.6M382.7M268.7M-911.8M78.6M342.23M72.12M-2.02B-194.23M147.75M70.24M32.63M12.59M3.02M4.23M-17.29M-27.36M-9.6M10.8M22.4M17.4M
Net Interest Income-25.3M31.7M-13.4M9.4M-82.2M-92.2M-112.2M-136.2M-142.4M-149.4M-154.6M-204.2M-219.3M-279.8M-138M-112.99M-125.83M-133.8M-80.38M000000000000
Interest Income69.9M74.4M108.7M120.5M12.9M1.4M4.3M4.6M6.3M3.8M700K1.3M1.3M1.3M2.34M1.86M1.28M1.16M4.53M000000000000
Interest Expense95.2M42.7M122.1M111.1M95.1M93.6M116.5M140.8M148.7M153.2M155.3M205.5M220.6M281.07M140.29M114.85M126.21M73.16M84.91M000000000000
Other Income/Expense-58M-33.1M-17.5M7.7M-52M-119.2M-103.1M-296.3M-180.7M-139.7M-133.3M-277.9M-231.6M-286.68M-175.36M-147.06M-124.93M-72M-81.6M737K-11.92M2.06M341K240K-2.41M-1.88M-1.66M3.8M5.4M5.1M-300K
Pretax Income663.6M681.2M865.1M676.1M1.59B2.36B1B-95.3M-418.6M1.23B415.3M177.2M48.1M-1.19B-61.66M227.39M-54.99M-2.09B-279.14M148.49M53.22M34.7M12.93M3.27M-250K-20.68M-29.02M-5.8M16.2M27.5M17.1M
Pretax Margin %16.08%16.61%21.46%16.78%32.66%41.92%26.53%-2.83%-13.01%40.23%14.66%6.55%1.9%-47.87%-3.08%12.71%-3.27%-127.58%-16.67%20.11%11.5%12.06%5.65%1.6%-0.13%-11.59%-30.95%-6.9%14.01%25.77%19.39%
Income Tax119.7M115.5M75.6M220.1M286.2M491.4M-108.6M-55.1M-307.3M475M84.5M45.6M30.8M-20.12M11.97M70.24M7.82M87.56M106.48M53.91M25.8M6.44M763K176K-429K169K-10.4M-2.1M5.8M9.8M5.7M
Effective Tax Rate %18.04%16.96%8.74%32.55%18.02%20.81%-10.84%57.82%73.41%38.6%20.35%25.73%64.03%1.69%-19.42%30.89%-14.22%-4.19%-38.14%36.31%48.48%18.56%5.9%5.39%171.6%-0.82%35.84%36.21%35.8%35.64%33.33%
Net Income543.9M565.7M789.5M456M1.3B1.87B1.12B-40.2M-111.3M755.5M330.8M131.6M17.3M-1.17B-73.63M157.15M-62.81M-2.18B-385.62M94.58M27.42M28.26M12.16M2.88M179K-20.85M-18.62M-3.7M10.4M17.7M11.4M
Net Margin %13.18%13.8%19.59%11.31%26.77%33.23%29.53%-1.19%-3.46%24.7%11.68%4.87%0.68%-47.06%-3.68%8.78%-3.74%-132.93%-23.03%12.81%5.93%9.82%5.32%1.41%0.09%-11.68%-19.86%-4.4%9%16.59%12.93%
Net Income Growth %-26.9%-28.35%73.14%-64.98%-30.43%67.82%2874.13%63.88%-114.73%128.39%151.37%660.69%101.48%-1492.79%-146.86%350.19%97.11%-464.35%-507.72%244.89%-2.95%132.29%322.07%1510.06%100.86%-11.98%-403.22%-135.58%-41.24%55.26%500%
Net Income (Continuing)543.9M565.7M789.5M456M1.3B1.87B1.11B-203.6M-111.3M755.5M330.8M131.6M17.3M-1.17B-73.63M157.15M-62.81M-2.18B-385.62M94.58M27.42M28.26M12.16M3.09M179K-20.85M-18.62M-3.7M10.4M17.7M11.4M
Discontinued Operations0000000000000000000000000000000
Minority Interest0000002.1M000000000000000000000000
EPS (Diluted)2.412.493.321.835.137.214.21-0.15-0.402.641.160.450.06-4.36-0.280.59-0.24-8.48-1.570.860.280.320.140.040.00-0.34-0.30-0.070.190.330.23
EPS Growth %-24.29%-25%81.42%-64.33%-28.85%71.26%2906.67%62.5%-115.15%127.59%157.78%650%101.38%-1457.14%-147.46%345.83%97.17%-440.13%-282.56%207.14%-12.5%128.57%300%-100.74%-13.33%-361.54%-134.21%-42.42%43.48%348.34%
EPS (Basic)-2.503.351.855.187.284.24-0.15-0.402.701.180.470.06-4.36-0.280.60-0.24-8.48-1.570.880.300.330.150.040.00-0.34-0.30-0.070.200.340.24
Diluted Shares Outstanding225.88M227.57M237.55M248.83M253.84M259.71M264.61M269.41M275.11M285.65M286.16M289.54M278.36M268.7M264.04M264.31M258.74M256.55M245.97M109.67M97.24M90.25M85.19M80.52M76.77M61.9M61.28M56.92M55.47M54.46M50.11M
Basic Shares Outstanding224.41M227.19M235.72M246.77M251.53M257.05M262.73M269.41M275.11M279.81M280.21M280.57M275.5M268.7M262.86M261.1M258.74M256.55M245.97M106.87M93.02M85.65M81.03M78.52M73.68M61.9M61.28M56.92M53.33M51.68M47.01M
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetHealthy
Cash FlowStable
Top Statement Risk

Post-pandemic revenue normalization

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Stagnant Revenue Amid Portfolio Transition

According to recent financial disclosures, Hologic's top-line growth has remained muted, with a 2.5% year-over-year increase in 2026Q1, reflecting the ongoing challenge of lapping elevated pandemic-era diagnostic volumes while attempting to pivot toward a more sustainable, core-driven revenue model across its four primary business segments.

The company's revenue trajectory appears to be in a consolidation phase, struggling to break out of the $1.0 billion quarterly plateau. This suggests that while the Panther diagnostic platform provides a recurring revenue floor, the lack of significant top-line acceleration indicates that new product adoption or market expansion is currently only offsetting the natural decay of COVID-related testing demand.

Structural Margin Volatility Remains Evident

As reported in quarterly filings, Hologic's gross margin profile has exhibited significant fluctuation, dropping to 37.5% in 2025Q2 before recovering to 56.0% in 2026Q1, which highlights the sensitivity of the company's cost structure to shifts in product mix and the inherent lumpiness of capital equipment sales.

The volatility in gross margins suggests that the company's profitability is highly dependent on the specific mix of high-margin molecular assays versus lower-margin imaging hardware. Investors should monitor whether the company can consistently maintain margins above the 55% threshold, as any sustained compression would imply a weakening of pricing power in its core diagnostic and surgical franchises.

Operating Efficiency Facing Scaling Headwinds

Based on the provided income statement data, Hologic's operating leverage appears constrained, as operating income has failed to scale consistently with revenue, evidenced by an operating margin of 22.6% in 2026Q1, which remains largely unchanged from the levels observed in the prior year's final quarter.

The inability to drive significant operating margin expansion despite stable revenue suggests that the company is currently absorbing elevated SG&A and R&D costs to support its specialized sales force and innovation pipeline. This indicates that management is prioritizing long-term market positioning over immediate bottom-line optimization, which may limit near-term EPS growth potential.

Earnings Volatility Obscures Underlying Performance

Analysis of the income statement reveals that Hologic's net income has been subject to significant quarterly variance, including a net loss in 2025Q2, largely driven by non-operating items and cost fluctuations that complicate the assessment of the company's true, normalized earnings power on a per-share basis.

The wide swings in EPS, ranging from a loss of $0.08 to a high of $1.03 over the last ten quarters, suggest that GAAP earnings are currently an unreliable indicator of operational health. Investors should focus on the consistency of cash generation rather than reported net income, as the latter is clearly impacted by one-time charges and the amortization of acquisition-related intangibles.

Risks of Over-Reliance on Installed Base

While the Panther platform is often cited as a competitive moat, the company's reliance on this hardware for recurring revenue may be vulnerable, as evidenced by the recent deceleration in growth and the potential for technological displacement in the highly competitive molecular diagnostics and imaging markets.

Short-term observers might argue that the 'razor-razorblade' model is reaching a maturity point where the cost of acquiring new customers is rising faster than the lifetime value of the installed base. If the company fails to innovate its diagnostic menu or if hospital capital budgets continue to tighten, the current valuation may be difficult to justify given the lack of meaningful top-line momentum.

HOLX — Frequently Asked Questions

Quick answers to the most common questions about buying HOLX stock.

What was Hologic, Inc.'s (HOLX) revenue in 2025?

For fiscal year 2025, Hologic, Inc. (HOLX) reported total revenue of $4.10B. This represents a 4549.1% increase compared to $88.2M in 1996.

Is Hologic, Inc. (HOLX) profitable?

Hologic, Inc. (HOLX) is profitable, generating $565.7M in net income for the fiscal year ending 2025 with a net profit margin of 13.8%.

What is Hologic, Inc.'s operating profit margin?

Hologic, Inc. (HOLX) reported an operating income of $714.3M, resulting in an operating profit margin of 17.4%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Hologic, Inc.'s gross profit and gross margin?

Hologic, Inc. (HOLX) generated $2.50B in gross profit for the year, representing a gross profit margin of 61.0%. This demonstrates the company's core pricing power and production efficiency.